PYC
Director Trades
| Date | Director | Value |
|---|---|---|
| A. Tribe | $35,000,000 |
Company News
PYC Therapeutics advances groundbreaking treatment for Phelan-McDermid syndrome
PYC Therapeutics (ASX: PYC) has made a breakthrough with its main drug candidate for the potential treatment of neurodevelopmental disorder Phelan-McDermid Syndrome (PMS). New studies by PYC have found it can restore the deficient protein that causes PMS in neurons, the brain cells in which the disorder occurs. The neurons in which these results have […]
Phylogica achieves milestone in drug study aimed at treating childhood blindness
Biotechnology company Phylogica (ASX: PYC) is one step closer to finding a treatment for the leading cause of childhood blindness, achieving a major milestone in its human ‘retina in a dish’ study. The company today reported results from its flagship drug program, in which its proprietary drug delivery technology was used on a 3D model […]
Phylogica’s cell penetrating platform linked to effective administration of drugs for genetic eye disease
A drug delivery platform developed by biotechnology company Phylogica (ASX: PYC) has been shown to be the most effective method of administering anti-sense oligonucleotide (ASO) medications to patients with genetic eye disease. A competitive evaluation test on animal models using Phylogica’s proprietary cell penetrating platform demonstrated the technology could significantly increase the effectiveness of an […]
Phylogica’s cell peptide delivery platform achieves early success in human cell studies for blinding eye diseases
Perth-based biotech company Phylogica (ASX: PYC) has reported positive early stage results from a pilot study of human cells using its proprietary drug delivery technology to create a treatment for blinding genetic eye diseases. The study delivered an anti-sense oligonucleotide (ASO) drug cargo into human retinal pigment epithelial cells using Phylogica’s cell penetrating peptide (CPP) […]
Phylogica obtains successful time-course study results for flagship CPP platform
Biotechnology company Phylogica (ASX: PYC) has unveiled favourable lab results in relation to its time-course studies in animals, with superior performance to current benchmarks officially confirmed. The most recent animal model results also complement the single time point results published last month. The company announced that today’s results differentiated its platform on both efficacy and toxicity […]
Phylogica reports positive peptide vaccine T-Cell expansion results in vivo
Perth-based biotechnology company Phylogica (ASX: PYC) has announced a successful round of in vivo results in the evaluation of its cell-penetrating peptide (CPP) vaccine program. Peptides are potentially valuable as the basis for future world-leading drugs and Phylogica has been developing ways of delivering those drugs intracellularly to address targets that would otherwise be deemed […]
Purposeful cell targeting delivers commercial spoils for Phylogica
Biotech company Phylogica (ASX: PYC) has announced it has developed a new recombination enzyme, Cre, thereby supplementing its ongoing research into a proprietary in vitro drug delivery platform. Phylogica says its novel development is “well validated” and routinely used in biological research. Phylogica is currently developing the next generation of intracellular biological therapeutics which it […]
Phylogica’s peptide technology effective in development of cancer vaccine
Phylogica (ASX: PYC) has praised the effectiveness of its Functional Penetrating Peptide (FPP) technology to stimulate an immune response and extend cancer survival rates through recent testing on mice. The biotechnology company said first results showed that when combining FPPs with a tumour antigen, the average survival of mice with melanoma was extended by almost […]
Company Videos
No videos found.